BBIO vs VSTM
BBIO: BridgeBio translates genetic science into medicines for rare genetic diseases through a decentralized portfolio model, with an FDA-approved lead product in transthyretin amyloidosis and multiple late-stage programs approaching commercialization. VSTM: A biopharmaceutical company developing targeted therapies for RAS/MAPK pathway-driven cancers, with a newly FDA-approved combination treatment for KRAS-mutated ovarian cancer and a pipeline focused on direct KRAS G12D inhibition.
Side-by-side fundamentals
| Metric | BBIO | VSTM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $82.66 | $5.89 | |
| Market cap as of 2026-07-23 | $16.2B | $527M | |
| PEG as of 2026-07-23 | -3.61 | n/a | |
| Net margin as of 2026-07-23 | -124.4% | -391.2% | BBIO higher |
| Gross margin as of 2026-07-23 | +95.1% | +85.1% | BBIO higher |
| Operating margin as of 2026-07-23 | -90.5% | -344.6% | BBIO higher |
| ROE as of 2026-07-23 | -206.7% | -163.6% | VSTM higher |
| ROA as of 2026-07-23 | -65.8% | -91.6% | BBIO higher |
| Debt / equity as of 2026-07-23 | 8.27 | 1.01 | VSTM lower |
| Revenue growth (YoY) as of 2026-07-23 | +355.2% | +209.1% | BBIO higher |
| Revenue CAGR (3y) SEC XBRL | +86.3% | +97.0% | VSTM higher |
| Beta as of 2026-07-23 | 0.97 | 0.38 | |
| 1-year return as of 2026-07-22 close | +79.6% | +11.8% | BBIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.